Lectenz® Bio is developing novel products that employ our unique Lectenz® reagents and GlycoSenseTM technology, to speed up and simplify the detection and discovery of disease biomarkers.
These products enable targeting glycan biomarkers of clinical significance for investigation and leveraging them for advancing human health. Glycan-based biomarkers are particularly important for disease diagnosis and clinical treatment, yet their discovery and detection is challenging, due to the lack of glycan-specific reagents and tools. We are meeting this important need by developing innovative technologies in the glycosciences that will advance critical research and clinical applications. We are excited about helping to improve human health in this underexploited area.
The company’s mission is to develop technologies that enable novel glycoscience applications, provide services that enhance glycan biomarker detection, and deliver tools that advance research and clinical applications.
Glycosensors and Diagnostics, LLC d/b/a Lectenz® Bio, was established to develop enabling technologies for applications in glycoscience. The company was spun-out from the research group of Prof. Robert J. Woods at the Complex Carbohydrate Research Center (CCRC), located at the University of Georgia (UGA). The company established operations in 2009 at Innovation Gateway (formerly the Georgia BioBusiness Center), home to several biotechnology companies in Georgia’s Innovation Crescent, and is proximal to the CCRC (pictured). In 2013, the company established its satellite operations in San Diego, California as a resident company of Johnson & Johnson Innovation, JLABS. In 2016, the company graduated from JLABS and relocated the San Diego site to the San Diego Science Center. In 2017, as part of commercialization the company rebranded as Lectenz® Bio.
Since establishing operations, the company has started collaborations with experts in academia and industry and secured non-dilutive funding through grants, contracts, and partnerships. The company has received multiple awards, honors, and recognitions. These accomplishments facilitated the validation of key aspects of the Lectenz® platform, expanded the core technology base to include the GlycoSenseTM platform, led to the development of the Lectenz® product pipeline, and allowed the company to pursue expanded patent protection including the recent issuance of the company’s first patent for a small molecule glycomimetic with therapeutic potential as a flu inhibitor.